Objective: To attempt to determine the relative value of preclinical cardiac electrophysiology
data (in vitro and in vivo) for predicting risk of torsade de pointes (TdP) in clinical use …

Prolongation of the QT interval and the cardiac action potential have been linked to a
potentially fatal but rare tachyarrhythmia known as Torsades de Pointes (TdP). Nonclinical …

Assessment of proarrhythmic toxicity of newly developed drugs attracts significant attention
from drug developers and regulatory agencies. Although no guidelines exist for such …

The long and growing list of non-antiarrhythmic drugs associated with prolongation of the QT
interval of the electrocardiogram has generated concern not only for regulatory interventions …

Background and purpose: The regulatory guidelines (ICHS7B) recommending inhibition of
the delayed rectifier K+ current (IKr), carried by human ether‐a‐go‐go‐related gene (hERG) …

Medicinal products that, as an unwanted effect, prolong the QT interval of the
electrocardiogram (ECG) can trigger episodes of polymorphic ventricular dysrhythmias …

INTRODUCTION: Drugs that delay cardiac repolarization pose potential safety risks to
patients and cause serious regulatory concern because of the link between QT interval …

Proarrhythmias due to drug‐induced QT prolongation are the second most common cause
for drug withdrawal and have caused increasing concern. Two new International …

Following reports of death from cardiac arrhythmias with drugs like terfenadine and
cisapride, the International Conference for Harmonization formulated a guidance (E14) …

Background and purpose: Assessing the proarrhythmic potential of compounds during drug
development is essential. However, reliable prediction of drug‐induced torsades de pointes …